MirZyme is built by a team of committed and experienced individuals working at the forefront of medical research and business.
Mr Mike Vousden
Mike Vousden has been a chartered accountant for over 25 years. He is responsible for all the financial aspects of the company.
Dr May Rezai
May Rezai obtained her PhD in 2021 and has been working with MirZyme from its inception. She is also the Chair of a UK-wide community based charity.
Dr Allyah Abbas-Hanif
Clinical Development Lead
Allyah Abbas-Hanif is an experienced pharmaceutical physician with more than a decade of proficiency in taking drugs from concept to global markets. She is trained in cardiology with an interest in maternal health.
Non Executive Directors
Julia Elizabeth King, Baroness Brown of Cambridge, DBE FREng FRS is a British
engineer and crossbench member of the House of Lords. She was a managing director at Rolls Royce and a member of the governing board of the European Institute of Innovation and Technology.
Mr Sami Ahmad
Sami Ahmad is CFO of Trecora Resources, a public NYSE-listed (TREC) leading
company in chemicals based in Houston, Texas. Sami has an MBA in finance from the University of Chicago.
Dr Wenda Ramma
Wenda Ramma has a Ph.D. in Vascular Biology and an Executive MBA from the UCLA. Wenda is the Medical Science Liason (Cardiovascular) at Bristol-Myers Squibb. At Amgen Wenda supported the launch of Repatha and other cardiovascular products.
Dr Malcolm Barratt-Johnson
Malcolm Barratt-Johnson is a Physician Scientist and the past president of the Royal Society of Medicine (Pharmaceutical Medicine). He is a lead medical assessor for MHRA and EMA. Malcolm is the MD of PharmaMedic Consultancy Limited.
Mr Kevin Holland
Kevin Holland is a health adviser helping Life Sciences companies gain market
access, patient access and commercialisation for new therapies. He was the head at Baxter’s leading a $600m business.
Dr Duncan McHale
Duncan McHale is supporting MirZyme's strategy and the clinical development of the
pipeline of therapeutics. He was the head of Translational Sciences at AstraZeneca.
Mrs Jane de Vries
Product Valuation Advisor
Jane has 17 years of pharmaceutical experience at GSK where she was a Senior Director and Value Evidence Leader within GSK’s global Value Evidence and Outcomes function, focussing on global payer and patient value evidence generation.
Dr Keqing Wang
Keqing Wang is a Vascular Scientist with clinical experience of Chinese hospitals. She was involved in the development of anticancer drug PEP005 which was later acquired by LEO Pharma for $2.875 billion.